In the past two years, due to the strong cash flow driven by COVID-19, the industrial parks of Chinese IVD enterprises have been ready to land.

                                                    

 Shenzhen Mindray Bio-Medical Electronics Co.,Ltd.

Wuhan Optics Valley Base (the second global headquarters)

Dangshan Mindray Medical Technology Industrial Park

On June 20, 2020, Mindray Medical Wuhan Base started construction in Optics Valley. The project has a total investment of 4.5 billion CNY, including two sub-projects of Wuhan Research Institute and Manufacturing Base, with a total construction area of about 620,000 square meters. Become Mindray Bio-Medical Electronics’ second global headquarters base.

 

 

In addition, in December 2020, Shenzhen Mindray Biomedical Electronics Co., Ltd. signed a contract with the People's Government of Dangshan County, Anhui Province, and Mindray Bio-Medical Electronics will invest in the construction of Mindray Medical Technology Industrial Park in Dangshan County. After several months of research and planning, this medical technology industrial park has been positioned as Mindray's Dangshan production base, becoming one of Mindray's main production bases in the country. According to the plan, the Dangshan base will invest 400 million CNY in advance, start construction in October 2021, put it into use at the end of 2022, and start production in the first quarter of 2023.

 

After the park is completed, it will become Mindray Medical's fourth largest manufacturing base in the world.

The total investment scale of the two bases: over 4.9 billion CNY.

 

 

Sansure Biotech Inc

Sansure (Shanghai) Gene Technology Co., Ltd. Industrial Park

Sansure Biotech‘s products have served nearly 150 countries and regions around the world, especially the COVID-19 " Sansure program" has become the leading anti-epidemic nucleic acid detection program in many countries around the world. The groundbreaking of the Shanghai Industrial Park is a new starting point and a new milestone for Sansure Biotech to be based in China and go to the world.

Rendering of Sansure Biotech (Shanghai) Gene Technology Co., Ltd. Industrial Park

Investment scale: 350 million CNY

 

Xiamen Biotime Biotechnology Co.,Ltd.

Biotime Biotechnology POCT Industrial Park

 

The Biotime Biotechnology POCT Industrial Park construction project is located on the southwest side of the intersection of Maolin Road and Haixiang Avenue, Haicang District, Xiamen, covering a total area of about 86,000 square meters, with a planned construction area of about 260,000 square meters. The park is planned to be completed and put into operation in 2024. After the park is put into operation, it is estimated that the annual output value will exceed 2 billion CNY. It will further enhance product research and development capabilities, improve scale output benefits, build an ecosystem for industrial development, and achieve economic and social benefits.

 

Rendering of the completion of Biotime Biotechnology POCT Industrial Park

Investment scale: about 1.2 billion CNY

 

 

Hangzhou Biotest Biotech CO.,LTD

Anhui Biotest Biotech Industrial Park

 

Anhui Biotest Biotech Industrial Park is located in Yi'an District, Tongling City, Anhui Province. Hangzhou Biotest Biotech CO.,LTD is an enterprise engaged in the R&D and production of high-end consumables, reagent raw materials and other products. It aims to build a high-end domestic biomedical industry. The product line of consumables and reagent raw materials truly realizes a complete closed loop from raw materials to finished products, and contributes to the development of China's high-end consumables and reagent raw materials production capacity.

 

Aerial view of the completion of Anhui Biotest Biotech Industrial Park

Investment scale: 1 billion yuan

 

 

Wuhan Easy Diagnosis Biomedicine Co.,Ltd.

Mingde Biotechnology Industrial Park

 

Wuhan Mingde Biotechnology Industrial Park started construction on February 22, 2021, with a total investment of about 1 billion CNY and a total construction area of 120,000 square meters. After completion, it will become a world-class and domestic leading intelligent manufacturing base for in-vitro diagnostic products, providing overall medical informatization solutions based on the five centers, helping Wuhan Easy Diagnosis Biomedicine become a leading enterprise in real-time, accurate and intelligent diagnosis.

Rendering of Mingde Biotechnology Industrial Park

 Investment scale: 1 billion CNY

 

The Beijing Genomics Institute

BGI Qingdao Health Medical Industrial Park

BGI said that with the rapid popularization and wide application of genetic testing technology in the two fields of reproductive health and tumor prevention and control, the market size of genetic testing reagents and testing services is rapidly increasing. Efficiently cover the testing service market in Shandong and surrounding provinces and cities.

Investment scale: 470 million yuan to be invested

Autobio Diagnostics CO.,Ltd.

Antu Biological In Vitro Diagnostic Industrial Park

Following the completion of the first-phase project of Antu Biological In Vitro Diagnostic Industrial Park, the main building of the second-phase project has been fully capped, and the third-phase project is also being accelerated. The Antu Biological In Vitro Diagnostic Industrial Park under construction is a key construction project in Henan Province, with a construction area of more than 500,000 square meters.

 

 

In June 2020, Autobio Diagnostics announced that the total amount of funds raised by the proposed non-public offering of shares will not exceed 3.28 billion CNY. The funds raised will be invested in the Antu Biological In Vitro Diagnostic Industrial Park

 (Phase III) project and the Antu Biological In Vitro Diagnostic Industrial Park

. Marketing network construction projects and replenishment of working capital projects.

 

Maccura Biotechnology Co.,Ltd

Tianfu International Bio-city IVD Industrial Park

Tianfu International Bio-city IVD Industrial Park, the project plans to build a number of production lines such as blood cell diagnostic reagents, coagulation diagnostic reagents, blood type diagnostic reagents, blood sugar test strips, colloidal gold detection, other blood diagnostic reagents and cleaning solutions, dedicated to R&D and Produce innovative varieties of medical devices that include key innovative technologies, reach international advanced levels and have good market prospects.

Investment scale: 1 billion CNY

 

 

Guangzhou Wondfo Biotech Co.,Ltd

Wanfu Biological Shenzhou Road Park

The total investment of Wanfu Bio-Shenzhou Road Park is 550 million CNY, covering an area of 14,000 square meters and a total construction area of 60,000 square meters. After completion, it will add 100 million people/year of disease detection product production capacity. The new annual output value is about 1 billion CNY.

The opening of the new park will strongly promote the upgrading of Wondfo Biotech 's R&D, production and intelligent manufacturing, push the industry to move towards the middle and high-end links of the global value chain, empower the industrial intelligent manufacturing with technological innovation, and strive to improve the advanced industrial foundation and the modernization of the industrial chain. Create another highland for high-quality economic development.

 

Investment scale: 550 million yuan.